Title : BTK/ITK dual inhibitors: Modulating immunopathology and lymphopenia for COVID-19 therapy.

Pub. Date : 2021 Jan

PMID : 32640487






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Here, we summarize the current knowledge of BTK/IL-2-inducible T-cell kinase (ITK) signaling in immunopathology and lymphopenia and discuss the potential of BTK/ITK dual inhibitors such as ibrutinib in modulating immunopathology and lymphopenia, for COVID-19 therapy. ibrutinib IL2 inducible T cell kinase Homo sapiens